Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Hydroxychloroquine is protective to the heart, not harmful: A systematic review

Prodromos, C., New Microbes and New Infections, doi:10.1016/j.nmni.2020.100747
Aug 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Review concluding that HCQ/AZ does not cause Torsade de Pointes or related deaths, HCQ decreases cardiac events, and HCQ should not be restricted in use for COVID-19 patients because of fear of cardiac mortality.
Reviews covering hydroxychloroquine for COVID-19 include Al-Bari, Brouqui, Colson, Derwand, Gao, Goldstein, Hecel, IHU, Kaur, Li, Loo, Matada, Roussel, Sahraei, Todaro, Vigbedor.
Prodromos et al., 20 Aug 2020, peer-reviewed, 3 authors.
This PaperHCQAll
Hydroxychloroquine is protective to the heart, not harmful: a systematic review
C C Prodromos, T Rumschlag, T Perchyk
New Microbes and New Infections, doi:10.1016/j.nmni.2020.100747
Hydroxychloroquine (HCQ) has been shown to be at least somewhat effective in treating patients with coronavirus disease 2019 . Recently the US Food and Drug Administration and Centers for Disease Control and Prevention warnings of fatal cardiac toxicity from torsades de pointes (TDP) arrhythmia from HCQ receipt have been made, notwithstanding the long safe provision of HCQ to treat lupus and rheumatoid arthritis. This has resulted in restricted access of HCQ for COVID-19 treatment. We hypothesized that HCQ and azithromycin have not been reported to cause significant acute cardiac arrhythmic mortality. We performed a literature search for the effects of HCQ and azithromycin on the heart. No TDP or related deaths were found to have been reported as a result of HCQ and azithromycin receipt in the peer-reviewed literature. On the contrary, HCQ and azithromycin were both found to substantially reduce cardiac mortality and also decrease thrombosis, arrhythmia and cholesterol in treated patients in recent peer-reviewed studies and meeting presentations. HCQ and azithromycin do not cause TDP cardiac mortality; rather, HCQ decreases cardiac events. HCQ should not be restricted in COVID-19 patients out of fear of cardiac mortality.
Conflict of interest None declared.
Al-Darraji, Haydar, Chelvarajan, Tripathi, Levitan et al., Azithromycin therapy reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction: potential therapeutic targets in ischemic heart disease, PLoS One
Alia, Jm, Does hydroxychloroquine combat COVID-19? A timeline of evidence, J Am Acad Dermatol
Asli, Abdullah, Chong, Metussin, Momin et al., Case report: right bundle brunch block and QTc prolongation in a patient with novel coronavirus disease (COVID-19) treated with hydroxychloroquine, Am J Trop Med Hyg
Atlanta, None, Abstract
Azimian, Gultekin, Hata, Atkinson, Ely et al., Fatal antimalarial-induced cardiomyopathy: report of 2 cases, J Clin Rheumatol
Belizna, Hydroxychloroquine as an antithrombotic in antiphospholipid syndrome, Autoimmun Rev
Bun, Taghji, Courjon, Squara, Scarlatti et al., QT interval prolongation under hydroxychloroquine/azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection, Clin Pharmacol Ther
Chen, Liu, Liu, Liu, Xu et al., A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19
Chen, Wang, Lin, Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia, Clin Toxicol (Phila)
Chorin, Wadhwani, Magnani, Dai, Shulman et al., QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin, Heart Rhythm
Chowdhury, Rathod, Gernsheimer, A rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID-19, Acad Emerg Med
Da, Xue, Yi, Ban, None
Erkan, Yazici, Peterson, Sammaritano, Lockshin, A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome, Rheumatology
Esmon, Inflammation and thrombosis, J Thromb Haemost
Fanouriakis, Kostopoulou, Alunno, Aringer, Bajema et al., update of the EULAR recommendations for the management of systemic lupus erythematosus, Ann Rheum Dis
Farkas, Myth-busting: azithromycin does not cause torsade de pointes or increase mortality
Gupta, Joshi, Chester-Wasko, Sharma, Association of hydroxychloroquine use and incident atrial fibrillation in systemic lupus erythematosus: a retrospective study
Hfsa, ). Caution recommended on COVID-19 treatment with hydroxychloroquine and azithromycin for patients with cardiovascular disease
Hooks, Bart, Vardeny, Westanmo, Adabag, Effects of hydroxychloroquine treatment on QT interval, Heart Rhythm
Hung, Wang, Lin, Wang, Chiou et al., Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: a nationwide populationbased cohort study, Int J Clin Pract
Izmirly, Costedoat-Chalumeau, Pisoni, Khamashta, Kim et al., Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibodyassociated cardiac manifestations of neonatal lupus, Circulation
Konig, Li, Petri, Hydroxychloroquine blood levels and risk of thrombotic events in systemic lupus erythematosus
Liu, Li, Zhang, Kwong, Li et al., Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis, Drug Des Devel Ther
Mathieu, Pereira, Tournadre, Soubrier, Cardiovascular effects of hydroxychloroquine: a systematic review and meta-analysis, Ann Rheum Dis
Mercuro, Yen, Shim, Maher, Mccoy et al., Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19), JAMA Cardiol
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis
Morgan, Patel, Dvorkina, Suspected hydroxychloroquineassociated QT-interval prolongation in a patient with systemic lupus erythematosus, J Clin Rheumatol
Nmni Prodromos, Hydroxychloroquine is protective
Nord, Shah, Rinaldi, Weisman, Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature, Semin Arthritis Rheum
O'laughlin, Mehta, Wong, Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine, Case Rep Cardiol
Ohara, Nakamura, Watanabe, Cao, Yamazaki et al., Azithromycin can prolong QT interval and suppress ventricular contraction, but will not induce torsade de pointes, Cardiovasc Toxicol
Olding, Cartwright, Controversial doc in Trump's ear calls malaria drug study 'garbage, Daily Beast
Pastick, Okafor, Wang, Lofgren, Skipper et al., Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19), Open Forum Infect Dis
Petri, Lakatta, Magder, Goldman, Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis, Am J Med
Rempenault, Combe, Barnetche, Gaujoux-Viala, Lukas et al., Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis, Ann Rheum Dis
Rho, Oeser, Chung, Milne, Stein, Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors, Arch Drug Inf
Ruiz-Irastorza, Egurbide, Pijoan, Garmendia, Villar et al., Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus, Lupus
Saleh, Gabriels, Chang, Kim, Mansoor et al., The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection, Circ Arrhythm Electrophysiol
Schrezenmeier, Dörner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat Rev Rheumatol
Shapiro, Levy, The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients, Oncotarget
Sharma, Wasko, Tang, Vedamurthy, Yan et al., Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients, J Am Heart Assoc
Sullivan, Ohio pharmacy board restricts prescriptions for experimental coronavirus treatment drugs
Swank, Mccartan, Pharmacovigilance memorandum-review of hydroxychloroquine-chloroquine
Van Halm, Nurmohamed, Twisk, Dijkmans, Voskuyl, Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study, Arthritis Res Ther
Yang, Leong, Sia, Wang, Wei, Long-term hydroxychloroquine therapy and risk of coronary artery disease in patients with systemic lupus erythematosus, J Clin Med
Yu, Li, Chen, Zhou, Wang et al., Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19, Sci China Life Sci
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop